SOMERSET, N.J. – August 9, 2022 – Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that it has reached an agreement to acquire Metrics Contract Services (Metrics), a full-service specialty Contract Development and Manufacturing Organization (CDMO) with a facility in Greenville, North Carolina, for $475 million from Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma). Upon completion, the acquisition will strengthen Catalent’s capabilities in integrated oral solid formulation development, manufacturing, and packaging to help customers simplify and accelerate their programs, while also expanding Catalent’s capacity to handle highly potent compounds.
Metrics Contract Services,na division of Mayne Pharma, has successfully completed an inspection atnits Greenville, NC facility by the Agência Nacional de Vigilância nSanitária, or the Brazilian National Health Surveillance Agency n(ANVISA), for commercial manufacture of a branded oncology drug to be nmarketed in Brazil. This is the fourth international inspection to nevaluate the 126,000-sq-ft commercial manufacturing facility completed nin 2018.
Increases capacity with new equipment investment.
Metrics Contract Services, a division of Mayne Pharma, said that its facility in Greenville, NC, has successfully completed a Pharmaceuticals and Medical Devices Agency (PMDA) inspection for commercial manufacture of a branded oncology drug to be marketed in Japan.